BR0109770A - Uso de galantamina para o tratamento do comportamento neuropsiquiátrico associado com a doença de alzheimer - Google Patents

Uso de galantamina para o tratamento do comportamento neuropsiquiátrico associado com a doença de alzheimer

Info

Publication number
BR0109770A
BR0109770A BR0109770-9A BR0109770A BR0109770A BR 0109770 A BR0109770 A BR 0109770A BR 0109770 A BR0109770 A BR 0109770A BR 0109770 A BR0109770 A BR 0109770A
Authority
BR
Brazil
Prior art keywords
alzheimer
galantamine
disease
behavior associated
treat neuropsychiatric
Prior art date
Application number
BR0109770-9A
Other languages
English (en)
Inventor
Win Louis Julien Parys
Michael Pontecorvo
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR0109770A publication Critical patent/BR0109770A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"USO DE GALANTAMINA PARA O TRATAMENTO DO COMPORTAMENTO NEUROPSIQUIáTRICO ASSOCIADO COM A DOENçA DE ALZHEIMER". A invenção refere-se a galantamina que tem sido utilizada no tratamento de um número de doenças crónicas. Foi descoberto que a galantamina é segura e eficiente no tratamento da doença de Alzheimer. Os distúrbios neuropsiquiátricos são freq³entemente associados com a doença de Alzheimer. é demonstrado que a galantamina é também eficiente na redução ou na estabilização da incidência do comportamento neuropsiquiátrico observado nos pacientes com Alzheimer.
BR0109770-9A 2000-04-03 2001-03-28 Uso de galantamina para o tratamento do comportamento neuropsiquiátrico associado com a doença de alzheimer BR0109770A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19425900P 2000-04-03 2000-04-03
PCT/EP2001/003553 WO2001074339A2 (en) 2000-04-03 2001-03-28 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease

Publications (1)

Publication Number Publication Date
BR0109770A true BR0109770A (pt) 2003-02-04

Family

ID=22716898

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109770-9A BR0109770A (pt) 2000-04-03 2001-03-28 Uso de galantamina para o tratamento do comportamento neuropsiquiátrico associado com a doença de alzheimer

Country Status (20)

Country Link
EP (1) EP1272192A2 (pt)
JP (1) JP2003528913A (pt)
KR (1) KR20020086911A (pt)
CN (1) CN1430514A (pt)
AU (2) AU6584401A (pt)
BG (1) BG107093A (pt)
BR (1) BR0109770A (pt)
CA (1) CA2310926C (pt)
CZ (1) CZ20023543A3 (pt)
EE (1) EE200200554A (pt)
HR (1) HRP20020778A2 (pt)
HU (1) HUP0300566A3 (pt)
IL (1) IL152061A0 (pt)
MX (1) MXPA02009777A (pt)
NO (1) NO20024746L (pt)
PL (1) PL361272A1 (pt)
RU (1) RU2002129298A (pt)
SK (1) SK15422002A3 (pt)
WO (1) WO2001074339A2 (pt)
ZA (1) ZA200207935B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
KR100764330B1 (ko) * 2003-07-25 2007-10-05 에프. 호프만-라 로슈 아게 급성 및/또는 만성 신경학적 장애의 치료를 위한ｍＧｌｕＲ2 길항제 및 ＡＣｈＥ 억제제의 조합물
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
EP4088717A1 (en) 2008-03-27 2022-11-16 Chase Pharmaceuticals Corporation Use and composition for treating dementia
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
BG66818B1 (bg) * 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
CN107847504A (zh) * 2015-05-18 2018-03-27 斯奈普泰克发展有限责任公司 淀粉状蛋白β的加兰他敏清除
CN117957003A (zh) * 2021-09-09 2024-04-30 上海日馨医药科技股份有限公司 治疗神经退行性疾病的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9600080D0 (en) * 1996-01-04 1996-03-06 Chiroscience Ltd Resolution process
AU1738800A (en) 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
KR100437105B1 (ko) * 1998-12-24 2004-06-23 얀센 파마슈티카 엔.브이. 방출 조절형 갈란타민 조성물
CA2310990A1 (en) * 2000-04-03 2000-10-09 Michael Pontecorvo A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects

Also Published As

Publication number Publication date
AU6584401A (en) 2001-10-15
CA2310926A1 (en) 2000-10-04
SK15422002A3 (sk) 2003-04-01
IL152061A0 (en) 2003-05-29
EE200200554A (et) 2004-04-15
NO20024746L (no) 2002-11-28
KR20020086911A (ko) 2002-11-20
NO20024746D0 (no) 2002-10-02
CZ20023543A3 (cs) 2003-03-12
CA2310926C (en) 2002-10-15
EP1272192A2 (en) 2003-01-08
AU2001265844B2 (en) 2005-04-14
HRP20020778A2 (en) 2004-04-30
CN1430514A (zh) 2003-07-16
WO2001074339A3 (en) 2002-09-12
HUP0300566A3 (en) 2004-10-28
PL361272A1 (en) 2004-10-04
MXPA02009777A (es) 2003-03-27
WO2001074339A2 (en) 2001-10-11
BG107093A (bg) 2003-06-30
JP2003528913A (ja) 2003-09-30
HUP0300566A2 (hu) 2003-06-28
ZA200207935B (en) 2004-01-30
RU2002129298A (ru) 2004-03-27

Similar Documents

Publication Publication Date Title
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
BR0008926A (pt) Utilização de um extrato de uva, rico ouenriquecido em polifenóis e processo detratamento cosmético do corpo humano
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
BR0114913A (pt) Inibidores de metaloproteinase de espiro-pirimidina-2,4,6-triona
BR0111913A (pt) Análogos de gabapentina para distúrbios do sono
KR970704429A (ko) 심혈관 질환의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of cardiovascular diseases)
BR0010531A (pt) Composições e usos de et743 para tratamento de câncer
BR0114392A (pt) Formulação de vacina, método para produzir uma formulação de vacina, uso de uma preparação de vacina contra rsv dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por rsv
BR0312845A (pt) Tetratiomolibdato de tetrapropilamÈnio e compostos relacionados para terapias antiangiogênicas
EP0401903A3 (en) The use of vanilloids for the treatment of respiratory diseases or disorders
KR890011589A (ko) 벤즈아미드의 용도
BR0208405A (pt) Compostos de diidropirimina substituìdos com ciano e seu uso para tratar doenças
BR9812660A (pt) Composições e métodos para tratar distúrbios respiratórios
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
BR0112547A (pt) Processo para encontrar compostos que sejam adequados para o tratamento e/ou profilaxia de obesidade
BRPI0410654A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR0107960A (pt) Tratamento de condições alérgicas e inflamatórias
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
BR9908885A (pt) Medicamento para a profilaxia e/ou tratamento de mastocarcinoma, compreendendo um inibidor esteróide de aromatase
WO2001074339A3 (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
DE3875349D1 (de) Glykosaminoglykan zur behandlung von diabetischer mikroangiopathie.
NO990450L (no) Behandling av sinnslidelser

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009